CN87108190A - 新型氨基烷酰基-二苯并[d，g][1，3，6]二氧杂氮杂辛因及其制备方法 - Google Patents

新型氨基烷酰基-二苯并[d，g][1，3，6]二氧杂氮杂辛因及其制备方法 Download PDF

Info

Publication number: CN87108190A
Authority: CN; China
Prior art keywords: dioxazocines; dibenzo; formula; compound; chloro
Prior art date: 1986-12-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN198787108190A

Other languages

English (en)

Chinese (zh)

Inventor

拉茨格·罗萨

鲁萨·彼托茨

马顿·弗凯特

埃尼科·茨尔特·尼·基斯泽利

马丽亚·赫吉杜斯

伊斯特万·加克萨伊

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Egis Pharmaceuticals PLC

Original Assignee

Egis Pharmaceuticals PLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-12-30

Filing date

1987-12-28

Publication date

1988-07-13

1987-12-28 Application filed by Egis Pharmaceuticals PLC filed Critical Egis Pharmaceuticals PLC

1988-07-13 Publication of CN87108190A publication Critical patent/CN87108190A/zh

Status Pending legal-status Critical Current

Links

125000002924 primary amino group Chemical group [H]N([H])* 0.000 title claims abstract description 5
238000002360 preparation method Methods 0.000 title claims description 10
SKUQZRMWNACBLW-UHFFFAOYSA-N 4h-1,3,6-dioxazocine Chemical class C1OCC=NC=CO1 SKUQZRMWNACBLW-UHFFFAOYSA-N 0.000 title description 61
239000002253 acid Substances 0.000 claims abstract description 40
150000003839 salts Chemical class 0.000 claims abstract description 32
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims abstract description 13
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims abstract description 13
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims abstract description 13
229960002646 scopolamine Drugs 0.000 claims abstract description 13
150000001875 compounds Chemical class 0.000 claims description 95
238000000034 method Methods 0.000 claims description 46
125000004432 carbon atom Chemical group C* 0.000 claims description 27
239000002585 base Substances 0.000 claims description 26
-1 pyrrolidyl Chemical group 0.000 claims description 26
229910052799 carbon Inorganic materials 0.000 claims description 25
238000006243 chemical reaction Methods 0.000 claims description 18
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 16
239000003513 alkali Substances 0.000 claims description 14
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 10
150000001412 amines Chemical class 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 9
239000001257 hydrogen Substances 0.000 claims description 9
229910052739 hydrogen Inorganic materials 0.000 claims description 9
238000011282 treatment Methods 0.000 claims description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
125000001118 alkylidene group Chemical group 0.000 claims description 8
125000005843 halogen group Chemical group 0.000 claims description 8
230000010933 acylation Effects 0.000 claims description 7
238000005917 acylation reaction Methods 0.000 claims description 7
125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
125000000753 cycloalkyl group Chemical group 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 6
150000007524 organic acids Chemical class 0.000 claims description 5
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 5
NNWUEBIEOFQMSS-UHFFFAOYSA-N 2-Methylpiperidine Chemical compound CC1CCCCN1 NNWUEBIEOFQMSS-UHFFFAOYSA-N 0.000 claims description 4
125000000623 heterocyclic group Chemical group 0.000 claims description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
230000000648 anti-parkinson Effects 0.000 claims description 3
239000000939 antiparkinson agent Substances 0.000 claims description 3
125000004429 atom Chemical group 0.000 claims description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
125000002757 morpholinyl group Chemical group 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
150000007522 mineralic acids Chemical class 0.000 claims description 2
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 92
239000000460 chlorine Substances 0.000 description 65
239000000203 mixture Substances 0.000 description 38
238000001953 recrystallisation Methods 0.000 description 37
229910052801 chlorine Inorganic materials 0.000 description 29
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 27
238000010438 heat treatment Methods 0.000 description 25
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
238000002425 crystallisation Methods 0.000 description 20
230000008025 crystallization Effects 0.000 description 20
238000012360 testing method Methods 0.000 description 19
241001465754 Metazoa Species 0.000 description 14
239000007795 chemical reaction product Substances 0.000 description 14
239000012043 crude product Substances 0.000 description 14
239000003921 oil Substances 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
241000699666 Mus <mouse, genus> Species 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
239000000047 product Substances 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
150000007513 acids Chemical class 0.000 description 10
235000019441 ethanol Nutrition 0.000 description 10
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
239000013078 crystal Substances 0.000 description 9
239000002904 solvent Substances 0.000 description 9
230000037396 body weight Effects 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
230000008569 process Effects 0.000 description 7
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
230000001143 conditioned effect Effects 0.000 description 6
230000006837 decompression Effects 0.000 description 6
238000001035 drying Methods 0.000 description 6
230000004044 response Effects 0.000 description 6
231100001274 therapeutic index Toxicity 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
239000000654 additive Substances 0.000 description 5
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
JSUAJTLKVREZHV-UHFFFAOYSA-N 1-[4-(1-pyrrolidinyl)but-2-ynyl]pyrrolidine Chemical compound C1CCCN1CC#CCN1CCCC1 JSUAJTLKVREZHV-UHFFFAOYSA-N 0.000 description 4
BWSWWPSCZQSEOD-UHFFFAOYSA-N 3-chloro-5h-benzo[d][1,3,6]benzodioxazocine Chemical class O1COC2=CC=CC=C2NC2=CC(Cl)=CC=C21 BWSWWPSCZQSEOD-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
238000013019 agitation Methods 0.000 description 4
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 4
229960000836 amitriptyline Drugs 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
150000003613 toluenes Chemical class 0.000 description 4
239000003643 water by type Substances 0.000 description 4
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical class ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 3
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000003187 abdominal effect Effects 0.000 description 3
229910052794 bromium Inorganic materials 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 3
229960002456 hexobarbital Drugs 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical class CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 3
239000004310 lactic acid Substances 0.000 description 3
235000014655 lactic acid Nutrition 0.000 description 3
229960004194 lidocaine Drugs 0.000 description 3
239000010813 municipal solid waste Substances 0.000 description 3
229960002715 nicotine Drugs 0.000 description 3
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
230000000452 restraining effect Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
238000005406 washing Methods 0.000 description 3
MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 2
MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 2
LDUMRUOQQANTOI-UHFFFAOYSA-N 1-(3-chloro-5H-benzo[d][1,3,6]benzodioxazocin-4-yl)ethanone Chemical class C(C)(=O)C1=C(C=CC=2OCOC3=C(NC=21)C=CC=C3)Cl LDUMRUOQQANTOI-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical class NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 description 2
IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010044565 Tremor Diseases 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000007059 acute toxicity Effects 0.000 description 2
231100000403 acute toxicity Toxicity 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
229960001076 chlorpromazine Drugs 0.000 description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
230000006872 improvement Effects 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
230000001788 irregular Effects 0.000 description 2
231100000636 lethal dose Toxicity 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
239000011707 mineral Substances 0.000 description 2
150000002780 morpholines Chemical class 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000003495 polar organic solvent Substances 0.000 description 2
229960001989 prenylamine Drugs 0.000 description 2
229960001404 quinidine Drugs 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
239000008096 xylene Substances 0.000 description 2
NWCHELUCVWSRRS-SECBINFHSA-N (2r)-2-hydroxy-2-phenylpropanoic acid Chemical compound OC(=O)[C@@](O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-SECBINFHSA-N 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
FPZAMNOXVVYEPG-UHFFFAOYSA-N 7-chloro-2-methyl-5-phenyl-3H-1,4-benzodiazepin-3-amine Chemical compound CC1=NC2=C(C(=NC1N)C1=CC=CC=C1)C=C(C=C2)Cl FPZAMNOXVVYEPG-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
208000004130 Blepharoptosis Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
241000766026 Coregonus nasus Species 0.000 description 1
206010052895 Coronary artery insufficiency Diseases 0.000 description 1
206010015995 Eyelid ptosis Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
150000001263 acyl chlorides Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
230000003257 anti-anginal effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
229950009941 chloralose Drugs 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
QPJORFLSOJAUNL-UHFFFAOYSA-N dibenzo[a,d][7]annulene Chemical compound C1=CC2=CC=CC=C2CC2=CC=CC=C21 QPJORFLSOJAUNL-UHFFFAOYSA-N 0.000 description 1
GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
235000015320 potassium carbonate Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
201000003004 ptosis Diseases 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
210000003497 sciatic nerve Anatomy 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000004575 stone Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229960001032 trihexyphenidyl Drugs 0.000 description 1
QDWJJTJNXAKQKD-UHFFFAOYSA-N trihexyphenidyl hydrochloride Chemical compound Cl.C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 QDWJJTJNXAKQKD-UHFFFAOYSA-N 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Anesthesiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CN198787108190A 1986-12-30 1987-12-28 新型氨基烷酰基-二苯并[d，g][1，3，6]二氧杂氮杂辛因及其制备方法 Pending CN87108190A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU865513A HU198194B (en)	1986-12-30	1986-12-30	Process for production of new derivatives of dioxazocin and medical compositions containing them
HU5513/86		1986-12-30

Publications (1)

Publication Number	Publication Date
CN87108190A true CN87108190A (zh)	1988-07-13

Family

ID=10970381

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN198787108190A Pending CN87108190A (zh)	1986-12-30	1987-12-28	新型氨基烷酰基-二苯并[d，g][1，3，6]二氧杂氮杂辛因及其制备方法

Country Status (26)

Country	Link
JP (1)	JPS63174978A (cs)
KR (1)	KR880007502A (cs)
CN (1)	CN87108190A (cs)
AT (1)	AT389304B (cs)
AU (1)	AU596258B2 (cs)
BE (1)	BE1001240A3 (cs)
CH (1)	CH675877A5 (cs)
CS (1)	CS270579B2 (cs)
DD (1)	DD267038A5 (cs)
DE (1)	DE3744549A1 (cs)
DK (1)	DK691087A (cs)
ES (1)	ES2006539A6 (cs)
FI (1)	FI875767A7 (cs)
FR (1)	FR2609030B1 (cs)
GB (1)	GB2199827B (cs)
GR (1)	GR872083B (cs)
HU (1)	HU198194B (cs)
IL (1)	IL84976A (cs)
IT (1)	IT1233443B (cs)
NL (1)	NL8703150A (cs)
NO (1)	NO169230B (cs)
PL (1)	PL151402B1 (cs)
SE (1)	SE465429B (cs)
SU (1)	SU1575938A3 (cs)
YU (1)	YU235287A (cs)
ZA (1)	ZA879733B (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU201318B (en) *	1987-12-31	1990-10-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing dioxazoline derivatives and pharmaceutical compositions comprising same
ATE91487T1 (de) *	1989-10-20	1993-07-15	Akzo Nv	Dibenzodioxazecin- und dibenzodioxaazacycloundecin-derivate.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2659M (fr) *	1963-04-25	1964-08-14	Millot Lab	Médicament a base de dérivé de la phénothiazine.
HU174126B (hu) *	1977-08-02	1979-11-28	Egyt Gyogyszervegyeszeti Gyar	Sposob poluchenija novykh proizvodnykh dibenzo-kvadratnaja skobka-d,g-kvadratnaja skobka zakryta-kvadratnaja skobka-1,3,6-kvadratnaja skobka zakryta-dioksazocina
HU195491B (en) *	1985-12-20	1988-05-30	Egyt Gyogyszervegyeszeti Gyar	Process for production of optically active 2-chlor-12-/3-/dimethil-amin/-2-methil-prophil/-12h-dibenzol /d,g/ /1,3,6/-diaxazocine and medical compositions containing such compounds
HU201318B (en) *	1987-12-31	1990-10-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing dioxazoline derivatives and pharmaceutical compositions comprising same

1986
- 1986-12-30 HU HU865513A patent/HU198194B/hu not_active IP Right Cessation
1987
- 1987-12-22 YU YU02352/87A patent/YU235287A/xx unknown
- 1987-12-28 CN CN198787108190A patent/CN87108190A/zh active Pending
- 1987-12-29 SE SE8705187A patent/SE465429B/sv not_active IP Right Cessation
- 1987-12-29 FR FR878718272A patent/FR2609030B1/fr not_active Expired - Lifetime
- 1987-12-29 DK DK691087A patent/DK691087A/da not_active Application Discontinuation
- 1987-12-29 NO NO875465A patent/NO169230B/no unknown
- 1987-12-29 CH CH5095/87A patent/CH675877A5/de not_active IP Right Cessation
- 1987-12-29 NL NL8703150A patent/NL8703150A/nl not_active Application Discontinuation
- 1987-12-29 ZA ZA879733A patent/ZA879733B/xx unknown
- 1987-12-29 IL IL84976A patent/IL84976A/xx unknown
- 1987-12-29 DD DD87311670A patent/DD267038A5/de not_active IP Right Cessation
- 1987-12-29 ES ES8800216A patent/ES2006539A6/es not_active Expired
- 1987-12-29 BE BE8701495A patent/BE1001240A3/fr not_active IP Right Cessation
- 1987-12-29 CS CS8710091A patent/CS270579B2/cs unknown
- 1987-12-30 GB GB8730298A patent/GB2199827B/en not_active Expired - Lifetime
- 1987-12-30 FI FI875767A patent/FI875767A7/fi not_active Application Discontinuation
- 1987-12-30 KR KR1019870015470A patent/KR880007502A/ko not_active Withdrawn
- 1987-12-30 GR GR872083A patent/GR872083B/el unknown
- 1987-12-30 PL PL1987269812A patent/PL151402B1/pl unknown
- 1987-12-30 DE DE19873744549 patent/DE3744549A1/de not_active Withdrawn
- 1987-12-30 IT IT8723271A patent/IT1233443B/it active
- 1987-12-30 SU SU874203954A patent/SU1575938A3/ru active
- 1987-12-30 AT AT0345087A patent/AT389304B/de not_active IP Right Cessation
- 1987-12-30 AU AU83140/87A patent/AU596258B2/en not_active Ceased
1988
- 1988-01-04 JP JP63000045A patent/JPS63174978A/ja active Pending

Also Published As

Publication number	Publication date
FR2609030B1 (fr)	1991-05-31
HU198194B (en)	1989-08-28
GB8730298D0 (en)	1988-02-03
HUT47260A (en)	1989-02-28
BE1001240A3 (fr)	1989-08-29
IT1233443B (it)	1992-04-01
JPS63174978A (ja)	1988-07-19
AT389304B (de)	1989-11-27
YU235287A (en)	1988-10-31
CH675877A5 (cs)	1990-11-15
FR2609030A1 (fr)	1988-07-01
NO169230B (no)	1992-02-17
DK691087A (da)	1988-07-01
SU1575938A3 (ru)	1990-06-30
DD267038A5 (de)	1989-04-19
SE465429B (sv)	1991-09-09
DE3744549A1 (de)	1988-07-14
FI875767A0 (fi)	1987-12-30
SE8705187L (sv)	1988-07-01
NO875465L (no)	1988-07-01
FI875767A7 (fi)	1988-07-01
NO875465D0 (no)	1987-12-29
CS1009187A2 (en)	1989-11-14
ATA345087A (de)	1989-04-15
GB2199827B (en)	1990-10-03
CS270579B2 (en)	1990-07-12
IL84976A0 (en)	1988-06-30
GR872083B (en)	1988-04-27
AU596258B2 (en)	1990-04-26
NL8703150A (nl)	1988-07-18
ZA879733B (en)	1988-06-24
KR880007502A (ko)	1988-08-27
AU8314087A (en)	1988-06-30
GB2199827A (en)	1988-07-20
DK691087D0 (da)	1987-12-29
ES2006539A6 (es)	1989-05-01
IT8723271A0 (it)	1987-12-30
PL151402B1 (en)	1990-08-31
SE8705187D0 (sv)	1987-12-29
PL269812A1 (en)	1988-09-15
IL84976A (en)	1991-09-16

Legal Events

Date	Code	Title
1988-07-13	C06	Publication
1988-07-13	PB01	Publication
1990-02-21	C10	Entry into substantive examination
1990-02-21	SE01	Entry into force of request for substantive examination
1993-02-10	C01	Deemed withdrawal of patent application (patent law 1993)
1993-02-10	WD01	Invention patent application deemed withdrawn after publication

Publication	Publication Date	Title
CN1135982C (zh)	2004-01-28	含n-酰基-2,3-苯并二氮杂�衍生物的药物组合物的制备方法
CN1031992C (zh)	1996-06-12	苯醌衍生物及其药用
CN86102738A (zh)	1987-10-28	新的含硫5-取代苯并咪唑衍生物的制备方法
CN1214339A (zh)	1999-04-21	吡唑衍生物、其制备方法和在药物中的应用
CN1030757A (zh)	1989-02-01	苯并噻唑衍生物
CN1109052A (zh)	1995-09-27	嘧啶和吡啶衍生物，它们的生产和应用
CN86103398A (zh)	1986-12-03	生产抗坏血酸衍生物的方法
CN1040193A (zh)	1990-03-07	烷氧基-4(1h)-吡啶酮衍生物的制备
CN1017049B (zh)	1992-06-17	5，6-二氢-2-(取代的苯基)-1，2，4-三嗪-3，5(2h，4h)-二酮类化合物的制备方法
CN1077954A (zh)	1993-11-03	新的苯并吡喃衍生物
CN1036566A (zh)	1989-10-25	1，3，4，5-四氢苯并[c，d]哚类化合物
CN87104319A (zh)	1988-05-04	苯并吡喃衍生物
CN1071427A (zh)	1993-04-28	6-苯并嗪基和6-苯并噻嗪基-2，3，4，5-四氢哒嗪-3-酮
CN88100153A (zh)	1988-07-27	杂芳基3-氧-丙腈衍生物的制备方法
CN85109587A (zh)	1986-12-17	具有抗过敏活性的新的苯并噻吩类和苯并呋喃类化合物的制备方法
CN1138583A (zh)	1996-12-25	9-取代的2-(2-正烷氧基苯基)-嘌呤-6-酮类化合物
CN1033585C (zh)	1996-12-18	1，2，4-三唑并(1，5-α)嘧啶衍生物的制法
CN1013442B (zh)	1991-08-07	新双环化合物的制备方法
HK1044534A1 (en)	2002-10-25	Pyridazin-3-one derivatives and medicines containing the same
CN85108115A (zh)	1986-07-30	新低血糖剂的制备方法
CN87108190A (zh)	1988-07-13	新型氨基烷酰基-二苯并[d，g][1，3，6]二氧杂氮杂辛因及其制备方法
CN1079744A (zh)	1993-12-22	7-氧代-7H-吡啶并[1，2，3，-d，e][1，4]苯并嗪-6-羧酸及其酯
CN1015892B (zh)	1992-03-18	新的氨基酮的衍生物的制备方法
CN1571783A (zh)	2005-01-26	取代的烷基氨基哒嗪酮衍生物、其制备方法和含有这种衍生物的药用组合物
CN1079742A (zh)	1993-12-22	制备嘧啶衍生物及其医药上可用的盐的方法